Aruvant

Aruvant

Biotechnology, 151 W 42nd St, New York, 10036, United States, 11-50 Employees

aruvant.com

  • facebook
  • twitter
  • instagram
  • LinkedIn

phone no Phone Number: 64********

Who is ARUVANT

Aruvants mission is to bring hope to patients living with rare diseases by developing life changing and potentially curative gene therapies, with a near-term focus on sickle cell disease....

Read More

map
  • 151 W 42nd St, New York, New York, 10036, United States Headquarters: 151 W 42nd St, New York, New York, 10036, United States
  • 2018 Date Founded: 2018
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Billion and Over
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from ARUVANT

Aruvant Org Chart and Mapping

Employees

Sheila Mooney

Sr Director Product Quality

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Aruvant

Answer: Aruvant's headquarters are located at 151 W 42nd St, New York, 10036, United States

Answer: Aruvant's phone number is 64********

Answer: Aruvant's official website is https://aruvant.com

Answer: Aruvant's revenue is $1 Billion and Over

Answer: Aruvant's SIC: 2834

Answer: Aruvant's NAICS: 325412

Answer: Aruvant has 11-50 employees

Answer: Aruvant is in Biotechnology

Answer: Aruvant contact info: Phone number: 64******** Website: https://aruvant.com

Answer: Aruvants mission is to bring hope to patients living with rare diseases by developing life changing and potentially curative gene therapies, with a near-term focus on sickle cell disease. Aruvant is a part of the Roivant family of companies. We have a talented team with extensive experience in the development, manufacturing and commercialization of gene therapy products. We have an active research program with a lead product candidate in development for individuals suffering from sickle cell disease (SCD). Our lead product candidate, ARU-1801, an investigational lentiviral gene therapy, is currently in a clinical trial as a potential one-time curative treatment for SCD. Preliminary clinical data from the ongoing Phase 1/2 study demonstrated durable efficacy in reducing the negative impacts of SCD. We are preparing for the launch of our pivotal clinical trial in SCD. We continue to look for new people to add to our talented team.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access